Intrexon | XON - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Agenus USD 14.67M 1.35M 2026-03
Alaunos Therapeutics USD 1.07M 215K 2023-06
Amgen USD 95.64B 94.98B 2026-06
Anika Therapeutics 183.47M 4.09M 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
AstraZeneca USD 340M 144M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Gilead Sciences USD 247M 7M 2026-06
GlaxoSmithKline GBP 121M 46M 2026-06
Heron Therapeutics USD 600K 100K 2024-12
Incyte USD 582K 13K 2026-06
Intrexon USD 2K 5K 2024-06
Karyopharm Therapeutics USD 12.55M 66K 2026-03
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
MacroGenics USD 4.89M 1.55M 2026-03
MannKind USD 14.82M 2.38M 2026-06
Merck USD 525M 46M 2026-06
Novartis USD 462M 119M 2026-06
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Thermo Fisher Scientific USD 354M 11M 2026-03
Veracyte USD 2K 1000 2023-12
Xencor USD 7.35M 2.65M 2026-06